Scientists believe an effective HIV vaccine is within reach, utilizing mRNA technology similar to that which proved successful against COVID-19. However, this progress is threatened by the withdrawal of U.S. government funding and political scrutiny of mRNA vaccines.
For over four decades, HIV has evaded vaccine development, with hundreds of candidates failing in trials. The virus's ability to mutate rapidly and its complex envelope protein have presented significant challenges. Researchers have identified that an effective vaccine must induce specific antibodies capable of neutralizing diverse and rapidly changing HIV strains. The mRNA platform offers a significant advantage due to its speed and flexibility, allowing for rapid iteration and refinement of vaccine designs. This contrasts with traditional vaccine development, which can take years.
In early 2025, researchers like Linda-Gail Bekker, an infectious disease specialist at the University of Cape Town, were poised to initiate clinical trials for a new mRNA-based HIV vaccine. The project, however, was critically dependent on U.S. government funding, which has historically accounted for about 90 percent of global investment in HIV vaccine research. Upon President Donald Trump's return to office, an executive order freezing foreign aid led to the immediate cancellation of a $45 million contract from the U.S. Agency for International Development (USAID) intended for such trials. Numerous other funds, often channeled through the National Institutes of Health (NIH), were also affected, stalling critical research.
The challenge in creating an HIV vaccine lies in targeting the virus's envelope protein, which it uses to infect cells. However, much of this protein acts as a decoy, with the crucial parts being highly mutable. Early vaccine candidates failed because they elicited antibodies that could not keep pace with the virus's adaptations. Progress began in the late 2000s when researchers studied individuals who naturally developed broadly neutralizing antibodies capable of recognizing conserved features of the virus. This led to a strategy of designing vaccines that could guide the immune system through a complex, multi-step process to develop these antibodies, a method that was historically slow and labor-intensive.
The advent of mRNA technology, propelled by its success during the COVID-19 pandemic, has revolutionized this process. Instead of growing viral components, mRNA vaccines provide cells with instructions to produce the target protein. This allows for rapid design changes, reducing development time from years to days or months. This agility is particularly crucial for tackling a rapidly evolving virus like HIV.
Despite the promise of mRNA technology, challenges remain. Public acceptance has been affected by backlash and misinformation surrounding COVID-19 vaccines. Furthermore, early trials of mRNA HIV vaccine candidates have reported a side effect of chronic urticaria, or persistent hives, in a subset of participants. Researchers are investigating the cause, with some theories pointing to the HIV envelope protein itself. Strategies involving lower doses are being explored to mitigate this side effect while maintaining immune efficacy.
Amidst the funding cuts, other setbacks have emerged. The NIH has begun winding down its Consortia for HIV/AIDS Vaccine Development (CHAVD) program, a cornerstone of global research. Additionally, policies enacted under the Trump administration restricted collaborations with South African scientists, severing vital ties. This has created what experts describe as a "perfect storm" that jeopardizes progress in HIV vaccine science.
Philanthropic organizations and other governments have stepped in to partially fill the funding gap, allowing some trials to continue, albeit on a reduced scale. The Gates Foundation, for example, continues to invest significantly in HIV vaccine programs. However, these contributions are a fraction of the funding previously provided by U.S. federal agencies, and future U.S. government budgets propose further cuts to key research institutes like the National Institute of Allergy and Infectious Diseases.
Beyond funding and political hurdles, the scientific landscape has also shifted. The development of long-acting injectable preventive drugs for HIV has raised the bar for vaccine efficacy. While these drugs offer significant protection, a successful vaccine that provides long-term immunity with minimal doses could overcome barriers related to access, cost, and stigma associated with regular medical visits.
For researchers like Bekker, the current situation echoes past challenges in South Africa, where government AIDS denialism hindered treatment rollouts. The shift of political opposition to Washington, D.C., she warns, threatens to undermine decades of scientific progress. "When politics interferes in science, that is the death of scientific progress," Bekker stated, expressing concern that energy is being diverted from fighting the virus to combating administrative policies.